NCT00455949

Brief Summary

Analyze the possible effect of the progesterone levels of the hCG administration on the oocyte embryo quality. The primary endpoint of this study is the pregnancy rate.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 3, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 4, 2007

Completed
Last Updated

April 4, 2007

Status Verified

April 1, 2007

First QC Date

April 3, 2007

Last Update Submit

April 3, 2007

Conditions

Premature Luteinization

Eligibility Criteria

Age18 Years - 34 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Oocyte donors; age range: 18 - 34; BMI: 18 - 29; long protocol.

You may not qualify if:

  • PCO syndrome;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Instituto Valenciano de la Infertilidad

Valencia, Valencia, 46015, Spain

Location

Study Officials

  • Marco Melo, MD

    Instituto Valenciano de Infertilidad

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
DEFINED POPULATION
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 3, 2007

First Posted

April 4, 2007

Last Updated

April 4, 2007

Record last verified: 2007-04

Locations

ES(1)